Equine Welfare: Gene Doping, British Racing’s Proactive Move Against a New Integrity and Welfare Threat

In March 2025, the British Horseracing Authority announced a significant expansion of its equine anti-doping programme: the introduction of routine testing for gene doping, backed by a seven-figure investment in detection technology at LGC laboratory in Cambridgeshire. The move addressed an emerging threat rather than a documented one, the BHA explicitly confirmed there was no evidence of gene doping in British or international racing but chose to act proactively rather than wait for a case to emerge before developing detection capability.

What Is Gene Doping?

Gene doping is the genetic or cellular manipulation of an animal’s DNA, either through gene editing techniques (such as CRISPR) or the addition of genetic material into cells via gene transfer. The purpose, as a performance-enhancing intervention, would be to alter a horse’s physiology in ways that improve athletic performance or aid recovery, for example, through increased muscle mass, enhanced oxygen-carrying capacity in the blood, or accelerated tissue repair.

Unlike pharmaceutical doping, where a prohibited substance is administered and detectable in a sample, gene doping creates changes at the cellular level that do not require ongoing administration and may not produce the kind of chemical signatures that standard blood and urine tests are designed to detect. This makes gene doping a qualitatively different integrity threat from conventional doping, requiring novel detection methodologies rather than adaptations of existing analytical processes.

The Evidence Base

The BHA’s announcement was clear on the current evidentiary position: “There are no recorded cases of gene doping in British racing or across any other international racing jurisdictions.” However, the IFHA’s Gene Doping Control Subcommittee, established in 2016, has documented examples of genetic manipulation for performance purposes in other equestrian contexts. Specifically, polo ponies in Argentina have been subject to gene editing for performance purposes, demonstrating that the technical capability for such manipulation in horses exists and has been used in at least one competitive equestrian discipline.

The Horse & Hound’s reporting on the BHA announcement also noted broader concerns: “There are concerns over potential unintended consequences of genetic manipulation that could lead to health and welfare issues.” This is the welfare dimension that distinguishes gene doping from a pure integrity concern. A horse whose DNA has been manipulated, potentially by amateur or unregulated actors attempting to produce performance advantages without full understanding of the biological consequences, may face unpredictable health outcomes. Protecting horse welfare from such manipulation is therefore as much a welfare imperative as an integrity one.

The LGC Research Programme

The BHA’s investment in gene doping detection was channelled through LGC, a global life sciences company based in Cambridgeshire with an established role in British racing’s anti-doping laboratory work. Dr Edward Ryder at LGC, a member of the IFHA’s Gene Doping Subcommittee, led the research that produced the novel detection methods now deployed in routine sampling.

Dr James Scarth, director of LGC’s laboratory of animal sports testing, described the methodology as specifically designed for flexibility: “LGC’s team of expert scientists have developed novel and effective solutions to detect both transgenes and their delivery vectors in equine samples. These innovative methods have been developed with flexibility in mind, allowing us to add new genes should new threats emerge, ensuring the relevance of the technology for years to come.”

The tests are incorporated into both race day sampling and out-of-competition sampling, the two-pronged approach that forms the backbone of the BHA’s existing anti-doping regime.

The BHA’s Statement

BHA Acting Chief Executive Brant Dunshea framed the initiative in terms that emphasised both integrity and welfare:

“Testing for gene doping is a significant step forward for British racing and reinforces our commitment to safeguarding the welfare of our horses, protecting the thoroughbred breed and integrity of our competition. It’s essential that we are proactive in this space, and through investing in this cutting-edge research we now have the technological capabilities to detect and deter any attempts to exploit nefarious techniques that could give horses an unfair advantage.”

The reference to “protecting the thoroughbred breed” is significant. The thoroughbred racing horse is a defined genetic population accumulated over more than 300 years of selective breeding. Gene editing that introduced heritable changes which can be passed to offspring would not only affect the individual horse but potentially alter the breed’s genetic character over generations. The breeding industry’s commercial and historical investment in thoroughbred genetics makes this a concern that extends far beyond the immediate competitive context of any given race.

The FEI’s Parallel Action

Simultaneously with the BHA’s announcement, the International Equestrian Federation (FEI) strengthened its rules on gene doping, with updated regulations coming into force on 1 April 2025. The FEI explicitly defined genetic therapy, gene editing and genome editing, adding these to its prohibited substances list and confirming that FEI-accredited laboratories have the capacity to conduct testing.

The coordinated action between the BHA (covering British racing) and the FEI (covering international equestrian competition) reflects an international consensus around the seriousness of the emerging threat and the need for consistent regulatory frameworks across jurisdictions.

Wider Context

The British Equestrian Federation’s anti-doping rules for 2026 incorporate the FEI’s updated Equine Prohibited Substances List, which came into effect on 1 January 2026. The prohibited substances list also received updates in July 2025 (beta-2 agonists, Sildenafil, administering injections) and October 2025 (whereabouts and permanent import information, pre-race examinations and food chain rules), reflecting an ongoing programme of regulatory updating across the equine medicine landscape.

The gene doping initiative represents the most significant proactive expansion of British racing’s anti-doping programme in recent years, one that is motivated by welfare concerns and long-term breed integrity as much as by immediate competitive fairness.